Viridian Therapeutics, Inc. - VRDN STOCK NEWS

Viridian Therapeutics, Inc. (NASDAQ: VRDN) announced the appointment of Tony Casciano as Chief Commercial Officer (CCO) and the departure of Carrie Melvin from her role as Chief Operating Officer (COO). Casciano brings over 20 years of experience in biopharma, including leadership roles at Teal Bio and AMAG Pharmaceuticals. Under his leadership, Viridian aims to strengthen its commercial operation, particularly with its lead asset, VRDN-001, currently in a Phase 3 trial for thyroid eye disease (TED). The company is also pursuing additional therapies for TED. The management transition is seen as a critical step in the company’s growth, as it seeks to deliver novel therapies to underserved populations.

Viridian Therapeutics (Nasdaq: VRDN) announced the approval of non-qualified stock options for 350,000 shares to two new employees, as part of its Inducement Grants, approved by a majority of the independent directors on the Board. These grants, made on March 30 and April 3, 2023, have an exercise price equal to the closing stock price on the Grant Date. They will vest over four years, with 25% vesting after one year, followed by 36 equal monthly installments, contingent on continued employment. The company is advancing treatments for thyroid eye disease, including a Phase 3 trial for VRDN-001, showcasing its commitment to developing medicines for serious and rare diseases.

On March 8, 2023, Viridian Therapeutics (NASDAQ: VRDN) announced its financial results for Q4 and the full year 2022, highlighting notable advancements in its thyroid eye disease (TED) program. The company reported a net loss of $45.8 million for Q4 and $100.9 million for the year, primarily due to increased R&D expenses. They initiated the THRIVE Phase 3 trial for their lead product candidate, VRDN-001, with topline results expected in mid-2024. The firm anticipates initial results from a proof-of-concept study for chronic TED in Q2 2023. Viridian's cash reserves total $424.6 million, sufficient to fund operations into late 2025.

Viridian Therapeutics (NASDAQ: VRDN) has announced presentations at the 49th Annual Meeting of the North American Neuro-Ophthalmology Society from March 11-16, 2023, in Orlando, Florida. Key highlights include an oral presentation of ongoing Phase 1/2 trial data for VRDN-001, targeting thyroid eye disease (TED), scheduled for March 14. Additionally, four poster presentations will cover the clinical and mechanistic findings of their TED pipeline, which aims to improve treatment for patients. The company is advancing VRDN-001 through its THRIVE Phase 3 trial and planning further studies on other pipeline candidates like VRDN-002 and VRDN-003.

Viridian Therapeutics (Nasdaq: VRDN) announced on March 3, 2023, that its Compensation Committee approved the grant of non-qualified stock options for 337,000 shares to three new employees. These grants were made outside of the Amended and Restated 2016 Equity Incentive Plan and comply with Nasdaq Listing Rule 5635(c)(4). The exercise price is set at the closing stock price on the grant date, with shares vesting over four years. Viridian is focused on developing treatments for serious and rare diseases, particularly advancing its VRDN-001 candidate for thyroid eye disease through both a Phase 3 trial and a Phase 2 proof-of-concept trial.

Viridian Therapeutics (NASDAQ: VRDN) announced a webcast and conference call on March 8, 2023, at 8:00 a.m. ET to discuss its Q4 and full-year 2022 financial results. The session can be accessed via the company’s website under the ‘Events and Presentations’ section. Viridian focuses on developing best-in-class medicines for serious and rare diseases, with ongoing clinical trials for its lead candidate, VRDN-001, targeting thyroid eye disease (TED). The company is conducting a global Phase 3 trial named ‘THRIVE’ and a Phase 2 trial, broadening its pipeline with additional candidates aimed at improving treatment delivery for TED patients.

Viridian Therapeutics, Inc. (NASDAQ: VRDN) announced that its senior management will present at Cowen’s 43rd Annual Health Care Conference on March 8, 2023, at 1:30 p.m. ET in Boston, MA. A live webcast of the presentation will be available in the Investors section of Viridian's website. The company specializes in developing innovative medicines for serious and rare diseases, focusing on thyroid eye disease (TED). Currently, Viridian is advancing VRDN-001 through a global Phase 3 trial named ‘THRIVE’ and a Phase 2 proof-of-concept trial. The company aims to offer convenient treatment options for TED patients.

Viridian Therapeutics, a biopharmaceutical company focused on serious and rare diseases, will participate in a fireside chat at the SVB Securities Virtual Global Biopharma Conference on February 15, 2023, at 1:00 p.m. ET. The event will be accessible via a live webcast on Viridian's website, and a replay will be available afterward. Viridian is advancing its VRDN-001 candidate in global Phase 3 and Phase 2 trials for thyroid eye disease, aiming to deliver best-in-class therapies. The company also develops other candidates targeting autoimmune and rare diseases. For more information, visit viridiantherapeutics.com.

Viridian Therapeutics Appoints New CEO

Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company, announced the appointment of Scott Myers as President and CEO, effective February 6, 2023. Myers has over 30 years of experience in the biopharmaceutical sector, succeeding co-founder Jonathan Violin, Ph.D. Under Violin's leadership, the company advanced its first Phase 3 trial in Thyroid Eye Disease (TED). Myers aims to leverage his extensive background to transition Viridian into a fully-integrated biopharmaceutical company, focusing on clinical execution and growth. Additionally, he received an inducement award comprising stock options and restricted stock units.